Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
2(10%)
Results Posted
64%(9 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
11
52%
Ph phase_1
2
10%
Ph phase_2
4
19%
Ph not_applicable
2
10%
Ph phase_4
1
5%

Phase Distribution

2

Early Stage

4

Mid Stage

12

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
2(10.0%)
Phase 2Efficacy & side effects
4(20.0%)
Phase 3Large-scale testing
11(55.0%)
Phase 4Post-market surveillance
1(5.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.4%

14 of 17 finished

Non-Completion Rate

17.6%

3 ended early

Currently Active

2

trials recruiting

Total Trials

21

all time

Status Distribution
Active(2)
Completed(14)
Terminated(3)
Other(2)

Detailed Status

Completed14
Withdrawn2
unknown2
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
2
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (10.0%)
Phase 24 (20.0%)
Phase 311 (55.0%)
Phase 41 (5.0%)
N/A2 (10.0%)

Trials by Status

withdrawn210%
unknown210%
completed1467%
terminated15%
recruiting210%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT07147257Phase 1

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

Completed
NCT03651518Phase 2

Personalized Therapies in Inflammatory Complex Disease

Recruiting
NCT07128472Not Applicable

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

Recruiting
NCT06729463Not Applicable

IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients

Completed
NCT02451748Phase 4

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Completed
NCT02660580Phase 3

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT06005532Phase 3

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Unknown
NCT03759288Phase 2

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Terminated
NCT05683626

Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital

Unknown
NCT00730717Phase 2

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Withdrawn
NCT00731757Phase 2

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

Withdrawn
NCT02762955Phase 3

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis

Completed
NCT03210259Phase 3

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Completed
NCT02746380Phase 3

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Completed
NCT02871635Phase 3

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Completed
NCT04135508Phase 3

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

Completed
NCT02405780Phase 3

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Completed
NCT02850965Phase 3

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT02581345Phase 3

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Completed
NCT02260791Phase 3

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21